Characterization of Pre-analytical Sample Handling Effects on a Panel of Alzheimer's Disease-related Blood-based Biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) Working Group

Overview

Journal Alzheimers Dement

Specialties Neurology
Psychiatry

Date 2021 Nov 30

PMID 34845818

Citations 84

Authors

Inge M W Verberk

Els O Misdorp

Jannet Koelewijn

Andrew J Ball

Kaj Blennow

Jeffrey L Dage

Noelia Fandos

Oskar Hansson

Christophe Hirtz

Shorena Janelidze

Sungmin Kang

Kristopher Kirmess

Jana Kindermans

Ryan Lee

Matthew R Meyer

Dandan Shan

Leslie M Shaw

Teresa Waligorska

Tim West

Henrik Zetterberg

Rebecca M Edelmayer

Charlotte E Teunissen

Affiliations

Soon will be listed here.

Abstract

Introduction: Pre-analytical sample handling might affect the results of Alzheimer's disease blood-based biomarkers. We empirically tested variations of common blood collection and handling procedures.

Methods: We created sample sets that address the effect of blood collection tube type, and of ethylene diamine tetraacetic acid plasma delayed centrifugation, centrifugation temperature, aliquot volume, delayed storage, and freeze-thawing. We measured amyloid beta (Aβ)42 and 40 peptides with six assays, and Aβ oligomerization-tendency (OAβ), amyloid precursor protein (APP) , glial fibrillary acidic protein (GFAP), neurofilament light (NfL), total tau (t-tau), and phosphorylated tau181.

Results: Collection tube type resulted in different values of all assessed markers. Delayed plasma centrifugation and storage affected Aβ and t-tau; t-tau was additionally affected by centrifugation temperature. The other markers were resistant to handling variations.

Discussion: We constructed a standardized operating procedure for plasma handling, to facilitate introduction of blood-based biomarkers into the research and clinical settings.

Citing Articles

Serum biomarkers as prognostic markers for Alzheimer's disease in a clinical setting.

De Meyer S, Blujdea E, Schaeverbeke J, Adamczuk K, Vandenberghe R, Poesen K Alzheimers Dement (Amst). 2025; 17(1):e70071.

PMID: 39886322 PMC: 11780118. DOI: 10.1002/dad2.70071.

Inflammation biomarkers and Alzheimer's disease: A pilot study using NULISAseq.

Di Molfetta G, Pola I, Tan K, Isaacson R, Blennow K, Ashton N Alzheimers Dement (Amst). 2025; 17(1):e70079.

PMID: 39886321 PMC: 11780250. DOI: 10.1002/dad2.70079.

Association of rapid eye movement sleep latency with multimodal biomarkers of Alzheimer's disease.

Jin J, Chen J, Cavailles C, Yaffe K, Winer J, Stankeviciute L Alzheimers Dement. 2025; 21(2):e14495.

PMID: 39868572 PMC: 11848184. DOI: 10.1002/alz.14495.

Short-term variability of Alzheimer's disease plasma biomarkers in a mixed memory clinic cohort.

Clemmensen F, Gramkow M, Simonsen A, Ashton N, Huber H, Blennow K Alzheimers Res Ther. 2025; 17(1):26.

PMID: 39838483 PMC: 11748847. DOI: 10.1186/s13195-024-01658-7.

Equivalence of plasma and serum for clinical measurement of p-tau217: comparative analyses of four blood-based assays.

Chen Y, Albert A, Sehrawat A, Farinas M, Lopez O, Zeng X medRxiv. 2025; .

PMID: 39763537 PMC: 11703320. DOI: 10.1101/2024.12.26.24319657.

References

Hansson O, Rutz S, Zetterberg H, Bauer E, Hahl T, Manuilova E . Pre-analytical protocol for measuring Alzheimer's disease biomarkers in fresh CSF. Alzheimers Dement (Amst). 2020; 12(1):e12137. PMC: 7748029. DOI: 10.1002/dad2.12137. View

Chatterjee P, Pedrini S, Stoops E, Goozee K, Villemagne V, Asih P . Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer's disease. Transl Psychiatry. 2021; 11(1):27. PMC: 7801513. DOI: 10.1038/s41398-020-01137-1. View

Willemse E, van Uffelen K, Brix B, Engelborghs S, Vanderstichele H, Teunissen C . How to handle adsorption of cerebrospinal fluid amyloid β (1-42) in laboratory practice? Identifying problematic handlings and resolving the issue by use of the Aβ/Aβ ratio. Alzheimers Dement. 2017; 13(8):885-892. DOI: 10.1016/j.jalz.2017.01.010. View

De Meyer S, Schaeverbeke J, Verberk I, Gille B, De Schaepdryver M, Luckett E . Comparison of ELISA- and SIMOA-based quantification of plasma Aβ ratios for early detection of cerebral amyloidosis. Alzheimers Res Ther. 2020; 12(1):162. PMC: 7719262. DOI: 10.1186/s13195-020-00728-w. View

Brickman A, Manly J, Honig L, Sanchez D, Reyes-Dumeyer D, Lantigua R . Plasma p-tau181, p-tau217, and other blood-based Alzheimer's disease biomarkers in a multi-ethnic, community study. Alzheimers Dement. 2021; 17(8):1353-1364. PMC: 8451860. DOI: 10.1002/alz.12301. View

Hansson O, Batrla R, Brix B, Carrillo M, Corradini V, Edelmayer R . The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau. Alzheimers Dement. 2021; 17(9):1575-1582. DOI: 10.1002/alz.12316. View

Abdelhak A, Huss A, Kassubek J, Tumani H, Otto M . Serum GFAP as a biomarker for disease severity in multiple sclerosis. Sci Rep. 2018; 8(1):14798. PMC: 6172254. DOI: 10.1038/s41598-018-33158-8. View

Altmann P, Leutmezer F, Zach H, Wurm R, Stattmann M, Ponleitner M . Serum neurofilament light chain withstands delayed freezing and repeated thawing. Sci Rep. 2020; 10(1):19982. PMC: 7672085. DOI: 10.1038/s41598-020-77098-8. View

Ovod V, Ramsey K, Mawuenyega K, Bollinger J, Hicks T, Schneider T . Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement. 2017; 13(8):841-849. PMC: 5567785. DOI: 10.1016/j.jalz.2017.06.2266. View

10.

Andreasson U, Perret-Liaudet A, van Waalwijk van Doorn L, Blennow K, Chiasserini D, Engelborghs S . A Practical Guide to Immunoassay Method Validation. Front Neurol. 2015; 6:179. PMC: 4541289. DOI: 10.3389/fneur.2015.00179. View

11.

Blennow K, Shaw L, Stomrud E, Mattsson N, Toledo J, Buck K . Predicting clinical decline and conversion to Alzheimer's disease or dementia using novel Elecsys Aβ(1-42), pTau and tTau CSF immunoassays. Sci Rep. 2019; 9(1):19024. PMC: 6911086. DOI: 10.1038/s41598-019-54204-z. View

12.

Verberk I, Thijssen E, Koelewijn J, Mauroo K, Vanbrabant J, de Wilde A . Combination of plasma amyloid beta and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. Alzheimers Res Ther. 2020; 12(1):118. PMC: 7523295. DOI: 10.1186/s13195-020-00682-7. View

13.

Jack Jr C, Bennett D, Blennow K, Carrillo M, Dunn B, Budd Haeberlein S . NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018; 14(4):535-562. PMC: 5958625. DOI: 10.1016/j.jalz.2018.02.018. View

14.

Lewczuk P, Ermann N, Andreasson U, Schultheis C, Podhorna J, Spitzer P . Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer's disease. Alzheimers Res Ther. 2018; 10(1):71. PMC: 6064615. DOI: 10.1186/s13195-018-0404-9. View

15.

Verberk I, Laarhuis M, van den Bosch K, Ebenau J, van Leeuwenstijn M, Prins N . Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study. Lancet Healthy Longev. 2022; 2(2):e87-e95. DOI: 10.1016/S2666-7568(20)30061-1. View

16.

Pesini P, Perez-Grijalba V, Monleon I, Boada M, Tarraga L, Martinez-Lage P . Reliable Measurements of the β-Amyloid Pool in Blood Could Help in the Early Diagnosis of AD. Int J Alzheimers Dis. 2012; 2012:604141. PMC: 3431090. DOI: 10.1155/2012/604141. View

17.

Simren J, Ashton N, Blennow K, Zetterberg H . Blood neurofilament light in remote settings: Alternative protocols to support sample collection in challenging pre-analytical conditions. Alzheimers Dement (Amst). 2021; 13(1):e12145. PMC: 7896630. DOI: 10.1002/dad2.12145. View

18.

Lachno D, Vanderstichele H, De Groote G, Kostanjevecki V, De Meyer G, Siemers E . The influence of matrix type, diurnal rhythm and sample collection and processing on the measurement of plasma beta-amyloid isoforms using the INNO-BIA plasma Abeta forms multiplex assay. J Nutr Health Aging. 2009; 13(3):220-5. DOI: 10.1007/s12603-009-0062-5. View

19.

Willemse E, van Maurik I, Tijms B, Bouwman F, Franke A, Hubeek I . Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project. Alzheimers Dement (Amst). 2018; 10:563-572. PMC: 6215060. DOI: 10.1016/j.dadm.2018.08.006. View

20.

Liu H, Chiu M, Lin C, Yang S . Stability of Plasma Amyloid-β 1-40, Amyloid-β 1-42, and Total Tau Protein over Repeated Freeze/Thaw Cycles. Dement Geriatr Cogn Dis Extra. 2020; 10(1):46-55. PMC: 7154287. DOI: 10.1159/000506278. View